Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.
∙ 1\. Individuals who are being administered with Jyseleca tablet in accordance with the Korean approved label therapeutic indications.
• Korean local label therapeutic indications of Jyseleca tablet. In the following participants, Jyseleca tablet should be used only if they do not respond appropriately or are intolerant to existing treatments.
• Following:
‣ Participants over 65 years of age.
⁃ Participants with a high cardiovascular risk.
⁃ Participants with malignancy.
• Rheumatoid arthritis:
‣ For treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
⁃ Jyseleca tablet may be used as monotherapy or in combination with methotrexate (MTX).
⁃ Jyseleca tablet should not be used in combination with biological DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors.
• Ulcerative colitis:
• a. For treatment of moderately to severely active ulcerative colitis in adults who have an inadequate response with, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or biological agents.
• The investigator should refer to local label and contraindications in Korea regarding the inclusion criteria.